A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg)

• ClinicalTrials.gov Identifier: NCT00665522
• Recruitment Status: Terminated
• First Posted: April 24, 2008
• Last Update Posted: April 10, 2015
• Sponsor: Alza Corporation, DE, USA
• Information provided by (Responsible Party): Alza Corporation, DE, USA

Study Description

Brief Summary:

The purpose of the study is to document the use of fentanyl HCl 40 mcg system under routine conditions and obtain a more comprehensive understanding of the safety of the system and complications that may not be spontaneously reported.

Condition or disease	Intervention/treatment
Pain	Drug: fentanyl iontophoretic transdermal system (40mcg) No Placebo; Drug: IV PCA with standard of care opioid analgesia

Detailed Description:

The safety of fentanyl HCl 40 mcg system has been evaluated in a number of research studies. Although this research included patients with acute moderate to severe pain after particular types of surgery, including abdominal, pelvic, and orthopedic procedures, the safety associated with use under conditions of routine post-operative clinical care may not have been completely characterized by the study database. This study will be a surveillance study on the risks associated with the usage of fentanyl HCl 40 mcg system under such conditions. Approximately 3,000 patients who have scheduled surgery and need treatment of acute moderate to severe post-operative pain and are treated with fentanyl HCl 40 mcg system in the hospital setting will be evaluated. In addition, a group of approximately 1,500 patients treated with opioid intravenous patient-controlled analgesia (IV PCA) will be matched to fentanyl HCl 40 mcg system patients with respect to (1) country (match will first be sought within the same research center, and extended to patients in the same country if no match is found), (2) pre-surgical physical condition and (3) surgery risk (high risk versus low risk). Patients at multiple research centers in multiple countries will be included. Patients with planned surgery and anticipated use of opioid pain management for post-operative care who are candidates for treatment with fentanyl HCl 40 mcg system or IV PCA opioid treatment will have the study explained and may participate after giving informed consent if they meet the study entry criteria. Enrollment in the study begins prior to their surgical procedure. Patients will receive treatment and care according to the standard practices at the study center, including: treatment choice, pain management set-up, and operation. Data collection in this observational (non-interventional) study will begin after informed consent is obtained and admission to the study center for the surgical procedure and will continue until discontinuation of fentanyl HCl 40 mcg system or IV PCA opioid treatment. Any significant changes in medical condition will be followed until they have resolved or have become medically stable. Patients will receive fentanyl iontophoretic transdermal system 40 mcg (fentanyl HCl 40 mcg delivered by patient activation over 10 minutes for a maximum of 6 doses/hour for up to 24 hrs or 80 total doses) or Intravenous Patient-Controlled Analgesia (IV PCA) opioid (medication choice, treatment regimen, and operation of the PCA pump to be consistent with standard practice at participating centers). Treatment duration to be determined by the treating physician.

Study Design

• Study Type: Observational
• Actual Enrollment: 218 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: A Prospective Safety Surveillance Study of IONSYS (Fentanyl HCl)
• Study Start Date: December 2007
• Actual Primary Completion Date: September 2008
• Actual Study Completion Date: September 2008

Groups and Cohorts

Group/Cohort	Intervention/treatment
001; fentanyl iontophoretic transdermal system (40mcg) No Placebo 40 mcg per dose maximum of 6 doses/hourtotal maximum 80 doses/24 hours	Drug: fentanyl iontophoretic transdermal system (40mcg) No Placebo; 40 mcg per dose, maximum of 6 doses/hour
002; IV PCA with standard of care opioid analgesia per 24 hour period	Drug: IV PCA with standard of care opioid analgesia; total maximum 80 doses/24 hours

Outcome Measures

Primary Outcome Measures :

1. The purpose of the study is to document the use of fentanyl HCl 40 mcg system under routine conditions and obtain a more comprehensive understanding of the safety of the system and complications that may not be spontaneously reported. [ Time Frame: Patients will receive treatment and care according to the standard practices at the study center, including: treatment choice, pain management set-up, and operation. ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

Approximately 3,000 patients who have scheduled surgery and need treatment of acute moderate to severe post-operative pain and are treated with fentanyl HCl 40 mcg system in the hospital setting will be evaluated. In addition, a group of approximately 1,500 patients treated with opioid intravenous patient-controlled analgesia (IV PCA) will be matched to fentanyl HCl 40 mcg system patients with respect to (1) country (match will first be sought within the same research center, and extended to patients in the same country if no match is found), (2) pre-surgical physical condition and (3) surgery risk (high risk versus low risk). Patients at multiple research centers in multiple countries will be included.

Criteria

Inclusion Criteria:

• Adult patients
• Planned surgery
• Planned use of fentanyl HCl 40 mcg system or IV Patient-Controlled Analgesia opioid treatment for postoperative pain

Exclusion Criteria:

- Pain resulting from emergency surgery

Contacts and Locations

Locations

Austria

Feldkirch, Austria

Graz, Austria

Klagenfurt, Austria

Linz, Austria

Salzburg, Austria

Wels N/A, Austria

Wien, Austria

Wr Neustadt N/A, Austria

Finland

Helsinki, Finland

Kuopio N/A, Finland

Germany

Aachen, Germany

Bad Dürkheim, Germany

Bergisch Gladbach, Germany

Berlin, Germany

Bonn, Germany

Hamburg N/A, Germany

Hannover, Germany

Kaiserslautern, Germany

Koblenz, Germany

Köln, Germany

München, Germany

Neubrandenburg, Germany

Sinsheim, Germany

Speyer, Germany

Wÿrzburg, Germany

Netherlands

Sneek, Netherlands

Sponsors and Collaborators

Alza Corporation, DE, USA

Investigators

• Study Director: Alza Corporation Clinical Trial; ALZA

More Information

Additional Information:

A Prospective Safety Surveillance Study of IONSYS (Fentanyl HCl) 

• Responsible Party: Alza Corporation, DE, USA
• ClinicalTrials.gov Identifier: NCT00665522
• Other Study ID Numbers: CR013201; C-2006-001
• First Posted: April 24, 2008
• Last Update Posted: April 10, 2015
• Last Verified: April 2015

Keywords provided by Alza Corporation, DE, USA:

Pain; Postoperative Analgesia; Patient-Controlled Opioids

Additional relevant MeSH terms:

Fentanyl; Analgesics, Opioid; Narcotics; Central Nervous System Depressants; Physiological Effects of Drugs; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Adjuvants, Anesthesia; Anesthetics, Intravenous; Anesthetics, General; Anesthetics